Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Ironwood Pharma Files to Begin China Phase III Trial of Linaclotide

publication date: Jul 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Ironwood Pharmaceuticals has filed a Clinical Trial Application with the SFDA for a China Phase III trial of linaclotide. Linaclotide is a peptide agonist aimed at treating abdominal pain in patients with irritable bowel syndrome accompanied by constipation. Ironwood, a Massachusetts pharma, still owns the China rights to the drug, although it has partnered linaclotide for much of the rest of the world. More details....

Stock Symbol: (NSDQ: IRWD)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
CBPF2016
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors